Celgene Corp
Change company Symbol lookup
Select an option...
CELG Celgene Corp
EW Edwards Lifesciences Corp
ETR Entergy Corp
ETP Energy Transfer Partners LP
ESS Essex Property Trust Inc
ESRX Express Scripts Holding Co
ES Eversource Energy
EPR EPR Properties
EONGY E.ON SE
EOG EOG Resources Inc
Go

Health Care : Biotechnology | Large Cap GrowthCompany profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Closing Price
$87.38
Day's Change
-0.23 (-0.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
87.83
Day's Low
86.89
Volume
(Average)
Volume:
3,396,257

10-day average volume:
3,739,692
3,396,257
  • Prev Close
    87.61
  • Today's Open
    87.31
  • Day's Range
    86.89-87.83
  • Avg Vol (10-day)
    3.7M
  • Last (time)
    4:00p ET 09/19/18
  • Last (size)
    40
  • 52-Wk Range
    74.13 - 147.17
    LowHigh
  • (10/02/17 - 05/21/18)
    17.87%
  • 33.8%
  • Market Cap
    61.5B
  • Shares Outstanding
    703.4M
  • 5.28
  • 16.61x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.3
  • 72.71
  • (% of float 08/31/18)
    1.74

Latest News

September 19, 2018
8:00 am ET
PR Newswire
5:44 am ET
BusinessWire
September 12, 2018
4:00 pm ET
BusinessWire
7:29 am ET
BusinessWire
September 11, 2018
9:31 am ET
PR Newswire
September 10, 2018
6:00 am ET
PR Newswire
August 24, 2018
8:44 am ET
MarketWatch
August 23, 2018
7:30 am ET
BusinessWire
August 16, 2018
8:00 am ET
Globe Newswire
August 14, 2018
12:27 pm ET
MarketWatch
August 08, 2018
8:00 am ET
BusinessWire
July 31, 2018
8:15 am ET
PR Newswire
July 28, 2018
10:30 am ET
MarketWatch
July 26, 2018
7:50 am ET
MarketWatch
7:30 am ET
BusinessWire
July 25, 2018
3:01 pm ET
BusinessWire
July 24, 2018
7:32 am ET
MarketWatch
July 17, 2018
8:00 am ET
PR Newswire
July 13, 2018
7:39 am ET
MarketWatch
July 11, 2018
4:00 pm ET
Globe Newswire
8:15 am ET
PR Newswire
July 10, 2018
9:27 am ET
BusinessWire
7:43 am ET
MarketWatch
7:37 am ET
MarketWatch
7:36 am ET
MarketWatch
7:30 am ET
BusinessWire
July 09, 2018
5:13 pm ET
MarketWatch
4:52 pm ET
BusinessWire
4:00 am ET
Globe Newswire
July 02, 2018
7:30 am ET
BusinessWire
June 29, 2018
8:35 am ET
MarketWatch
June 28, 2018
4:30 pm ET
BusinessWire
8:00 am ET
BusinessWire
June 26, 2018
7:30 am ET
PR Newswire
June 25, 2018
9:53 am ET
BusinessWire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.